Depomed is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia, and CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults. Besides, the Company provides Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults, and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.

Type
Public
HQ
Newark, US
Founded
1995
Size (employees)
490 (est)
Depomed was founded in 1995 and is headquartered in Newark, US
Report incorrect company information

Key People/Management at Depomed

Arthur Higgins

Arthur Higgins

President and Chief Executive Officer
Mark Booth

Mark Booth

Senior Vice President, General Manager Specialty Business Unit
Stan Bukofzer M.D

Stan Bukofzer M.D

Senior Vice President, Chief Medical and Scientific Officer
Matthew Gosling

Matthew Gosling

Senior Vice President and General Counsel
Sharon D. Larkin

Sharon D. Larkin

Senior Vice President, Human Resources and Administration
Sean P. McKercher

Sean P. McKercher

Senior Vice President, Operations and Business Relationships
Show more

Depomed Office Locations

Depomed has an office in Newark
Newark, US (HQ)
300 7999 Gateway Blvd
Show all (1)
Report incorrect company information

Depomed Financials and Metrics

Depomed Financials

Depomed's revenue was reported to be $380.72 m in FY, 2017
USD

Revenue (Q1, 2018)

128.4 m

Gross profit (Q1, 2018)

116.4 m

Gross profit margin (Q1, 2018), %

90.6%

Net income (Q1, 2018)

33.8 m

EBIT (Q1, 2018)

51.3 m

Market capitalization (14-Jun-2018)

443.2 m

Closing share price (14-Jun-2018)

7

Cash (31-Mar-2018)

101.7 m
Depomed's current market capitalization is $443.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

134.2 m390.4 m342.7 m455.9 m380.7 m

Revenue growth, %

191%(12%)33%

Cost of goods sold

7.1 m15.1 m67.9 m87.4 m72.6 m

Gross profit

127.1 m375.2 m274.8 m368.5 m308.1 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

76.5 m67.7 m51.5 m32.2 m94.5 m104.9 m104.8 m116.7 m110.5 m90.4 m100.5 m95.4 m128.4 m

Cost of goods sold

3.7 m4.7 m3.5 m3.1 m22.9 m20.9 m23.5 m21 m20.2 m17.8 m19.7 m17.4 m12 m

Gross profit

72.8 m63.1 m48 m29.1 m71.6 m83.9 m81.2 m95.7 m90.3 m72.7 m80.7 m78 m116.4 m

Gross profit Margin, %

95%93%93%90%76%80%78%82%82%80%80%82%91%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

244.7 m488.7 m101.1 m117.7 m126.9 m

Accounts Receivable

11.5 m27 m71.1 m102.1 m71.9 m

Inventories

10.1 m8.5 m10.5 m13 m13 m

Current Assets

337 m617.6 m309 m306.2 m230.9 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

195.3 m211.1 m546.7 m52.8 m94.1 m107.5 m182 m87.8 m90.4 m187.8 m113.2 m107.6 m101.7 m

Accounts Receivable

12.8 m17.3 m20 m23.5 m59.8 m68.4 m69.9 m79.5 m87 m67.5 m78.3 m77.2 m62.4 m

Inventories

8.5 m7.8 m7.3 m6.5 m10.4 m11.4 m10.9 m10.4 m11.3 m12 m10.4 m10.4 m5.4 m

Current Assets

313.3 m309.6 m632.5 m613.5 m232.2 m302.8 m292.6 m230.2 m260.9 m286.8 m219 m219.3 m193.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

43.3 m131.8 m(75.7 m)(88.7 m)(102.5 m)

Depreciation and Amortization

6.2 m12 m85.7 m106.8 m105.5 m

Inventories

4.3 m1.7 m9.3 m(3.7 m)(1.9 m)

Accounts Payable

16 m(2.7 m)(2.7 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

17.9 m12.7 m6.5 m(11.6 m)(21.7 m)(11.8 m)(20.9 m)(10.5 m)(12.9 m)(26.7 m)(53.4 m)(16 m)33.8 m

Depreciation and Amortization

2.5 m2.5 m2.5 m26.7 m27 m27 m27 m27 m26.3 m52.7 m26.9 m

Inventories

7.8 m7.8 m7.3 m6.5 m10.4 m11.4 m10.9 m10.4 m11.3 m873 k490 k10.4 m7.5 m

Accounts Payable

18.2 m3.2 m7.4 m11.3 m18.5 m(2.4 m)(2.7 m)7 m(2.1 m)
USDY, 2018

Financial Leverage

4.9 x
Show all financial metrics
Report incorrect company information

Depomed News and Updates

Controlled-Release Drug Delivery Technology Market Insights and Analysis for Period 2017-2027

Controlled-Release Drug Delivery Technology Market Insights and Analysis for Period 2017-2027 Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information